<SEC-DOCUMENT>0001144204-18-037096.txt : 20180703
<SEC-HEADER>0001144204-18-037096.hdr.sgml : 20180703
<ACCEPTANCE-DATETIME>20180703103747
ACCESSION NUMBER:		0001144204-18-037096
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180702
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180703
DATE AS OF CHANGE:		20180703

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOANALYTICAL SYSTEMS INC
		CENTRAL INDEX KEY:			0000720154
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				351345024
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23357
		FILM NUMBER:		18935088

	BUSINESS ADDRESS:	
		STREET 1:		2701 KENT AVE
		CITY:			WEST LAFAYETT
		STATE:			IN
		ZIP:			47906-1382
		BUSINESS PHONE:		3174634527

	MAIL ADDRESS:	
		STREET 1:		2701 KENT AVENUE
		CITY:			WEST LAFAYETTE
		STATE:			IN
		ZIP:			47906-1382
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv497955_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 8-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
July 2, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 14pt">BIOANALYTICAL
    SYSTEMS, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(Exact name of registrant as specified in its charter)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Indiana</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">0-23357 </FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">35-1345024</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of incorporation or organization)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2701 KENT AVENUE</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WEST LAFAYETTE, INDIANA</P></TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 45%; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">47906-1382</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">Registrant&rsquo;s telephone number, including
area code: (765) 463-4527</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company&#9;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 1.01 Entry into a Material Definitive Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Acquisition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 2, 2018, Bioanalytical
Systems, Inc. (the &ldquo;<U>Company</U>&rdquo;), through its wholly-owned subsidiary Cardinal Laboratories LLC (the &ldquo;<U>Purchaser</U>&rdquo;),
acquired (the &ldquo;<U>Acquisition</U>&rdquo;) substantially all of the assets of Seventh Wave Laboratories, LLC (the &ldquo;<U>Seller</U>&rdquo;),
a consulting-based contract research laboratory located in Maryland Heights, Missouri providing integrated services for discovery
and preclinical drug development, under the terms and conditions of an Asset Purchase Agreement, dated July 2, 2018, among the
Purchaser, the Company, the Seller and certain members of the Seller (the &ldquo;<U>Purchase Agreement</U>&rdquo;). The consideration
for the Acquisition consisted of $7,000,000 in cash, subject to certain adjustments and an indemnity escrow of $750,000, and 1,500,000
of the Company&rsquo;s common shares. The Company funded the cash portion of the purchase price for the Acquisition with cash on
hand and the net proceeds from the refinancing of its credit arrangements with First Internet Bank (&ldquo;<U>FIB</U>&rdquo;),
as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Purchase Agreement
contains customary representations, warranties, covenants (including non-competition requirements applicable to the selling parties
for a 4 year period) and indemnification provisions. As contemplated by the Purchase Agreement, on July 2, 2018 the Purchaser and
the Seller agreed to lease arrangements for certain premises in Maryland Heights, Missouri (the &ldquo;<U>Lease Arrangements</U>&rdquo;)
owned by SWL Properties LLC, an entity controlled by certain members of the Seller, including John E. Sagartz, President and Chief
Strategy Officer of the Seller and a newly elected member of the Company&rsquo;s Board of Directors (See Item 5.02 below). Under
the Lease Arrangements, the Purchaser agreed to lease the premises for a term of approximately 7 years, with two automatic 7 year
extensions unless terminated by the Purchaser with one hundred and eighty day prior written notice. Annual rent under the Lease
Arrangements for the initial term ranges from $390,000 for the first year to $440,987 for the seventh year, provided that the Lease
Arrangements provide the Purchaser with the option to purchase the premises prior to the end of the fifth lease year. The Lease
Arrangements include customary rights upon a default by landlord or tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Amendment to Credit Arrangements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">In
connection with the Acquisition, on July 2, 2018 the Company and FIB entered into an amendment to</FONT> the <FONT STYLE="font-size: 10pt">Credit
Agreement by and between the parties dated June 23, 2017 (as amended, the &ldquo;<U>Credit Agreement</U>&rdquo;) to (i) provide
the Company with an additional term loan (the &ldquo;<U>New Term Loan</U>&rdquo;) in the amount of $5,500,000, the proceeds of
which were used to fund a portion of the cash consideration for the Acquisition, and (ii) increase the Company&rsquo;s revolving
line of credit from $2,000,000 to $3,500,000 (the &ldquo;<U>Amended Facility</U>&rdquo;), which the Company may borrow from time
to time, subject to the terms of the Credit Agreement, including as may be limited by the amount of Company&rsquo;s outstanding
eligible receivables. The New Term Loan and the Amended Facility mature July 2, 2023 and June 30, 2019, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Amounts outstanding
under the New Term Loan bear interest at a fixed per annum rate of 5.06%, while interest accruing on the principal balance of the
Facility remains unchanged, at a floating per annum rate equal to the Prime Rate (generally defined as the highest rate identified
as the &ldquo;Prime Rate&rdquo; in The Wall Street Journal &ldquo;Money Rates&rdquo; column on the date the interest rate is to
be determined, or if that date is not a publication date, on the publication date immediately preceding) less Twenty-five (25)
Basis Points (0.25%). The New Term Loan requires monthly principal and interest payments equal to $78,091.42. The Company remains
obligated to pay accrued and unpaid interest on the outstanding balance under the Amended Facility on a monthly basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following its amendment,
the Company&rsquo;s obligations under the Credit Agreement (including with respect to the initial term loan made June 23, 2017)
are guaranteed by BAS Evansville, Inc., the Company&rsquo;s wholly owned subsidiary (&ldquo;<U>BASEV</U>&rdquo;), as well as the
Purchaser. The Company&rsquo;s obligations under the Credit Agreement and BASEV&rsquo;s and the Purchaser&rsquo;s obligations under
their respective Guaranties are secured by first priority security interests in substantially all of the assets of the Company,
BASEV, and the Purchaser respectively, as well as mortgages on the Company&rsquo;s and BASEV&rsquo;s facilities in West Lafayette,
Indiana and Evansville, Indiana, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The various restrictive
covenants under the Credit Agreement remain substantially consistent, provided that the parties agreed (i) to modify the computation
of the minimum debt service coverage ratio (but, not the ratio itself) to appropriately reflect relevant aspects of the Acquisition
and (ii) to convert the debt to equity ratio in the existing Credit Agreement to a cash flow coverage ratio whereby, beginning
with the fiscal quarter ended September 30, 2018, the ratio of the Company&rsquo;s total funded debt (as defined in the Credit
Agreement) as of the last day of each fiscal quarter to its EBITDA (as defined in the Credit Agreement) for the 12 months ended
on such date may not exceed 4.50 to 1.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing descriptions
of the Purchase Agreement, the First Amendment and the Lease Arrangements do not purport to be complete and are qualified in their
entirety by the terms and conditions of those agreements, copies of which will be filed as exhibits to the Company&rsquo;s Annual
Report on Form 10-K for the year ending September 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 2.01 Completion or Acquisition
or Disposition of Assets.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information set
forth in Item 1.01 with respect to the Acquisition is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 2.03 Creation of a Direct Financial
Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information set
forth in Item 1.01 with respect to the First Amendment and the Lease Arrangements is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 3.02 Unregistered Sales of Equity
Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Purchase
Agreement, the Company issued 1,500,000 of the Company&rsquo;s common shares to the Seller. The shares were issued in reliance
upon the exemption from the registration requirements of the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;),
provided by Section 4(a)(2) of the Securities Act as sales by an issuer not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information set forth in Item 1.01
with respect to the Acquisition is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 5.02 Departure of Directors or
Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 2, 2018, the
Board of Directors of the Company unanimously elected John E. Sagartz, President and Chief Strategy Officer of the Seller, as an
independent, Class III director. Mr. Sagartz&rsquo;s term will expire at the 2021 annual meeting of shareholders. The Board of
Directors has not determined the committees of the Board of Directors to which Mr. Sagartz will be named and the Company will disclose
that information once determined. Mr. Sagartz will not receive any compensation for his service as a director in addition to the
compensation he is to receive as an employee of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 7.01 Regulation FD Disclosure.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 2, 2018, the
Company issued a press release relating to the Acquisition, a copy of which is attached to this Current Report on Form 8-K as Exhibit
99.1 and is incorporated herein by reference. This information shall not be deemed &ldquo;filed&rdquo; for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;), or incorporated by reference in
any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a
filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01 Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The financial statements and pro forma financial
information with respect to the Acquisition required by Item 9.01 of Form 8-K will be included in an amendment to this Form 8-K
by not later than 71 calendar days after the date that the initial report on Form 8-K is required to be filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)&nbsp;&nbsp;Exhibits:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><A HREF="tv497955_ex99-1.htm" STYLE="-sec-extract: exhibit">99.1</A></TD><TD><A HREF="tv497955_ex99-1.htm" STYLE="-sec-extract: exhibit">Press Release dated July 2, 2018.</A></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; text-align: left"><FONT STYLE="font-size: 10pt">Bioanalytical Systems, Inc.</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; width: 31%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 15%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Date: July 3, 2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; white-space: nowrap"><FONT STYLE="font-size: 10pt">By:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/
    Jill C. Blumhoff</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Jill C. Blumhoff</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Chief Financial Officer,</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Vice President&mdash;Finance</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.8in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.8in; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit Index</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt"><U>Exhibit</U></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt"><U>No.
    Description</U></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 10%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; width: 88%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="tv497955_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="tv497955_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Press Release dated July
    2, 2018.</FONT></A></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.8in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.8in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.8in; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv497955_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD ROWSPAN="8" STYLE="font: 10pt Times New Roman, Times, Serif; width: 58%"><IMG SRC="image_001.jpg" ALT=""></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 15%">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right; white-space: nowrap; width: 25%">&#9;<FONT STYLE="font-size: 18pt; color: #F79646"><B>|
</B></FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: gray">NEWS RELEASE</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; white-space: nowrap">For more information:</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right; white-space: nowrap">Company Contact:</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; white-space: nowrap">Jill Blumhoff</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; white-space: nowrap">Chief Financial Officer &amp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; white-space: nowrap">Vice President of Finance</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; white-space: nowrap">Phone: 765.497.8381</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; white-space: nowrap">jblumhoff@BASinc.com</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BASi and Seventh Wave Laboratories Combine
Operations to Provide Broader Solutions and Greater Scientific Expertise to Clients</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>WEST LAFAYETTE, IN</B>, July 2, 2018 -- <B>Bioanalytical
Systems, Inc. (NASDAQ:BASI) </B>and <B>Seventh Wave Laboratories, LLC, </B>today announced that they have signed an asset purchase
agreement (APA) joining operations to provide broader solutions and greater scientific expertise to clients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BASi <FONT STYLE="background-color: white">provides contract
research services and niche instrumentation to the life sciences industry, primarily in drug research, discovery, and development
in commercial and academic settings. </FONT>The company&rsquo;s non-clinical toxicology laboratory provides clients with drug safety
and general toxicology services, including carcinogenicity studies, DART and juvenile toxicology studies. The company offers regulated
bioanalytical method development and analysis. In addition, the company provides non-clinical PK/PD from a purpose-built in vivo
discovery center that includes a dedicated vivarium utilizing BASi&rsquo;s proprietary Culex<SUP>&reg;</SUP> Automated Sampling
Systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: #FEFEFE">Seventh Wave Laboratories
provides consultative integrated services to assess safety and efficacy of pharmaceuticals and devices. Bioanalysis, pharmacokinetics,
and histopathology services cover discovery through regulatory approval, and are fully GLP compliant. The company&rsquo;s in vivo
services focus on discovery stage support. Unique pharmacology model development and special pharmacology models are also offered,
with emphasis on hepatitis B virus pharmacology using liver humanized chimeric models. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By combining offerings, the two companies expect to capitalize
on their collective skill sets, expertise, and assets to create a comprehensive portfolio highlighting:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Lead optimization and candidate selection</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">BASi Culex<SUP>&reg;</SUP> Automated Sampling Systems </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">In vivo toxicology and pharmacology</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">GLP in vivo services</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">GLP and non-GLP bioanalysis</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Histopathology including immunohistochemistry and image analysis</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Pharmacokinetics</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">In vitro and in vivo bioequivalence testing</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Established in 2003, Seventh Wave Laboratories has a proud history
and in 2017 generated annual revenues of approximately $11 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;For both BASi and Seventh Wave Laboratories, our success
has been built on a solid foundation of quality, on-time delivery and a commitment to providing personalized and responsive service
to our clients,&rdquo; said Philip Downing, senior vice president of preclinical services at BASi. &ldquo;We believe Seventh Wave&rsquo;s
scientific depth and expertise in histopathology, pharmacokinetics, investigative toxicology and pharmacology model development
perfectly complement BASi&rsquo;s offerings and make this combination an excellent strategic fit. By bringing our companies together,
we intend to provide the same dedication and focus our clients have come to expect, while delivering expanded options and more
comprehensive solutions. We are proud and very excited to begin this new venture with Seventh Wave.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">John Sagartz, DVM, PhD, DACVP, president and founder of Seventh
Wave Laboratories, added, &ldquo;We&rsquo;re so thrilled to be able to bring together these two organizations. Over the past 15
years, we&rsquo;ve engaged hundreds of clients to facilitate their discovery and development needs. With BASi, we add capabilities
that have often been requested, but have not been available through Seventh Wave alone. Through extensive collaborations over the
past several years, it is apparent that the two organizations share a focus on delivering quality and timely services. We expect
the enhanced capabilities and shared core values to facilitate enriched client interactions and further growth.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Transaction Summary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the terms of the APA, Seventh Wave Laboratories
received 1,500,000 Common Shares of BASI and approximately $7 million in cash (a portion of which remains in escrow) in exchange
for substantially all of its assets. In order to finance the cash component of the consideration, BASi entered into a new term
loan with First Internet Bank for $5.5 million and increased the borrowing availability under its existing line of credit from
$2.0 million to $3.5 million. As of the closing of the transaction, Seventh Wave Laboratories held approximately 17% of BASi&rsquo;s
issued and outstanding Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A Current Report on Form 8-K containing further details regarding
the APA and the transaction will be filed by BASi.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify"><B>About Bioanalytical Systems,
Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0">BASi is a pharmaceutical development company providing
contract research services and monitoring instruments to the world's leading drug development companies and medical research organizations.
The Company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new
drug to market. Visit <FONT STYLE="color: Blue"><U>www.BASinc.com</U></FONT> for more information about BASi.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify"><B>About Seventh Wave Laboratories,
LLC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #444444"><FONT STYLE="background-color: #FEFEFE">Seventh
Wave Laboratories is a consulting-based contract research laboratory located in Maryland Heights, Missouri that provides integrated
services for discovery and preclinical drug development. By integrating PK/ADME, bioanalysis, toxicology and pathology, the company
provides local, national and international clients a multidisciplinary environment that accelerates their program and goals with
focused strategy and execution. For more information, visit <FONT STYLE="color: Blue"><U>www.7thwavelabs.com</U></FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #444444">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify"><I>This release may contain forward-looking
statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes
in the market and demand for our products and services, the development, marketing and sales of products and services, changes
in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company's filings
with the Securities and Exchange Commission.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !_ 1L# 2(  A$! Q$!_\0
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M0U71)Y7#Q6-Q>V>KO'.=-6&3^7+Q%X:\0>$]<U7PCXQT&_\ #?B;1KEK;6-
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MBUP+F&-8O+B2W0Q--+^@<7^KCYR=BY/3)P,\9/?W/U-?D-_P2/P/@_\ %['
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MC_-4_P#!DO\ ,_%K_AG#_@KQ_P!'J>%__"<\$_\ SIJ/^&</^"O'_1ZGA?\
M\)SP3_\ .FK]H]P'?^(^IZ=0,#L>"#G!!'44X<@=.X'N.?Z=1^@H]H^T/_ (
MA[*/\U3_ ,&33^YO_@'XM?\ #.'_  5X_P"CU/"__A.>"?\ YTU'_#.'_!7C
M_H]3PO\ ^$YX)_\ G35^T>[L0>2>,=1^?4>W'X\TN,8XW'(!/?KG/T!H]HWL
MJ;](Q_!_U]X*E%]:G_@R?^?]?<?BW_PSA_P5X_Z/4\+_ /A.>"?_ )TU'_#.
M'_!7C_H]3PO_ .$YX)_^=-7[2$C('?/;U'K[8X.:7//;'?\ H/J<_P"<BCVK
MO:T+_P"".W?T#V</YJG_ (,E_F?BU_PSA_P5X_Z/4\+_ /A.>"?_ )TU'_#.
M'_!7C_H]3PO_ .$YX)_^=-7[2DCT)^G.,>OI2;LC(X /)/IWH]I+M#_P!![.
M'\T]5?\ B3V^\_%K_AG#_@KQG_D]7PN!@\?\(YX)Y(]/^+3TU_V;_P#@KV4D
MV?MK^%@Y5@A/AOP1A6*G!/\ Q:8Y"G'7J*_:<L ><\C(XZ#T/O\ Y[4*<@YR
M#DY!ZCVX_3TZ=J?M6U\-/9K^'&_Z.ZZ#Y([<\^BM[1]'?OUV;ZK[SC?AQIOB
MS1_A[X%TGQ]K47B3QUIG@_PQ8>,_$,"0Q0:[XKL=$L;;Q#K,,5O:V-O'%J>K
MPW=ZD<%E9PJLX6.U@3$2]I2#@ >@%+6:V1H'^?\ /YU QF5VX781A/F)8MR>
MA! ZG'7[H&,5/SV]#S[]N.,_GVJA( 92I8@($;:5(4 YQ\W8A0=Q!XQDBCOY
M*[ZZ+=_)$3DXI:7;=EJDKM>ZFWM=V5^Y-,X7G(*@8( ]1CEO7GIV]>:J2&1\
MK&#MZ(Q,BC( Y!4HY7(P0'(89(X&1^(?[>_[?OQ7^&'Q/UCX(?"&>Q\-?V!I
MEB?$GC=;&#5]>M]2U+2[/5FTW3H[V&]M]-2UTS4;:2:]-K=7\ERY>*6W1&+?
MD!X@^//QO\0:HFK:_P#&[XDW<]TJ2K*/%OB68WL:$MYD<,=Y&(GW'YHXH(HP
M1L2!0-I_9^%O CB3B; 83-ZV8Y?DV#S"E#$8-8AXS%8NO1J04H55@\'0E.G"
M<.9IU*D)-*,EI.)_&7BE]-WPX\.L_P QX8P>1\1<59KDN9RRO/:N KY/E&6Y
M97I5%3KPECLWQ*^MNES*+>$H2@\2W@Y3CB8NF?V;,,JT4H:3>I!AF$CJ^[=N
M)21R'0]2'WA0<=#@_CE^WM_P1'_8S_;8TG4-=T[P5HW[/_QV*7-SHOQ<^%NB
M6>@+JNHO%-)]F^(OA'3#8Z!XXT^XN)!<S7EW:0^(K6:,7%KK8C>ZLKS\ZOV:
M_C5^W)KWBJ#3_P!GSQOX^^(=S;3+/J7AO7_/\1^$K:V:)/,3Q&/%&H)IFCQ3
MD*(;M+^QOQN/EE60,?Z4OA5J_C_4O NC:Q\8_#>A>"/&\.GRW?BG1]'URUU?
M0=.E@5@;VWU6.4P0V<\*2W$D4T[BT4,C7$@1GKY[BW@S-?#+'8:5'B+)\7BJ
MU7E=+*L?4CF6&DGS)9IDN+IPG0IU'9\M95N:#4E!7C;]3\)/&[(_'/*\?6R_
M@WBW*<NI0YZ>89YEV$Q7#.<4(XCV4GE/$F68NO@,76ISIS]IA'2IXO#U*4J=
M9QE&2/\ +J_:R_92_:#_ & _CY/\(_BUI][X2\9^')[+Q)\/_'_A74[ZVTS7
MM#L]1=]"\:_#_78C%*DGVX13F,2#4_#NK>9!=+;S1PY_L>_X(2?\%?O$'[7F
MF2_LI?M)^(+?5/VB_ WAB76_ OCNY-O#??&KP+H:PVNIRZL%$<-U\1?#,!6\
MUY[.&(Z]I*RZ\;9;BUU5JZC_ (+R>$OV6?VK_P!B#XB:MX?^+GP;UGXZ?LQ+
M)\7/AZFB^.O!FI>*)+#1YX;#XD^"Y+:+4KB]O-,UWPE?W]R^G01F1?$FBZ!=
MHI:%EK^'3]G7XV^*OV:/CK\'?C]X'N&LO$WPC\?:!XTLI(9GM8KS3[.[1?$^
MC7QMVMVDTSQ+X9N-9T'5(&<QSZ?JEQ Z,KY'VD*4?$3A:5;&X.6'S[+Z=2E3
ME*G5I)5J%.-:%6CS\KJ4LSA&-.I!SG"A.,?91B^:+^D=3%<(\2*$,8JN39AR
MUXTW&A:SDZ3PTG!-4X8-R=2$XN,I^U<:EUR<O^MW S.FYP,AB1@Y(ZXS@DG@
MGJ>G!&> LC,J?*&R "JC!9AC)0#&W/&.0<=<'ORW@GQ5HOC?PGX6\:>&9/.\
M/^,_#NA>+M$G">7]ITGQ)I-KK.FSLO&#+9WD#E>"H8 _=^;YQ_;UO?C=IW[&
M'[4=_P#LWC4&^.=I\$?B!<?#0:-NEUZ+Q&GA^[*3>&H@4:3Q1;60N[CPQ%$Q
MDDU^.P6-6D9$K\$PU*56O#"N2A.>*CAI3JODC3E/$0HN523:480E.3D[Z>SE
MJE:WZK.<8P=5WE!0E4]V]G%1E/1)2>J2:24G:UK[/V1OC3\*CXJ'@7_A:7PU
M3QOYZVA\&_\ "?>%1XJ6[90ZVY\._P!IG5C/Y>9%MQ:"1@I;:5YKI=>\9>'/
M"=E'>^+/$?A_PM:3W!M(;WQ-KNFZ'9RWI7S4M(KG5)[2&>YV(S+%&QE*HY8?
M*QK^/#_@G#_P3Z_X(_?\%"?V3]!T71M=^)'AO]NW3-$>\^,?C5_C-\0M)_:*
M\&_%VTEG?5O$FE^$O$7B.[\"^(?"UKK$1CL2GA?4(Y-*B$>JZK#KWVO4G^R_
M^#E;3;"?]E3]D?P_K,LESI,W[7/PST+7IY9Y;..\T&32I],UB>ZO()%.GQ3:
M0\US<WB/(-/D+2J[B(D_1KA_#/B# Y']=QE*I6QE;"XFIB<NA!Q=*G7E]8P3
M>(7UK#5U2YJ$IJDYT^1[S47XJS:I3R[$YG6IX;V-*E&I1C0QO/&2G.$%#$*=
M!*A5@ZE/F4]5>7-#1M?T1VWQE^$]]-;V=E\4_AO>ZA>R0VMG86GCSPM/=WEW
M<L$AM+>VAU.26:XED8)%##&\DKG:BDD+72:?XT\/:KJVIZ%IGB#0-1U[1'"Z
M[H=AK6G7FL:(VV-E35]+MKB2_P!,<B1'Q=V\2N)8MI(F7=^%WPT_X)>_\$)/
M#'Q)^'OBKX667PW/Q.\+>,O#WB3X=?V?^V-\8?$=X?&NBW\.I>'GM?#=_P#&
M[5-/UF9=0MHI1I5UIMY;W90PRV[Q,8Z\P_;.?_AWK_P5^_9D_;BTU9]-^!O[
M<&G6O[+7[3K*\B:1IGQ L[>WM/AWXVNK6!HTBDNK.V\.PWMQ<K.SMX7O9_/,
MM\5'+'*<-B<3+"8+$9DJ\\'B<1@X8[+?J-7$XK"T_:1PT:7,VX8B$,1*G.*G
MS3I1C!/G7+M+,)X>B\5BHT%2AB,/AW'#8E8E1AB:E.G'$U'&%X>SG42]G\/(
MW-SMRV_HUU'6]/T?3[S5=6U&QTG3;"*6YO=2U.\MM/TZRME5&:XN[RZDBM;>
M&/>I>6>4(I;E^]<W??$SP!I.G:5K&K>/?!6DZ1X@B,_A_5M2\5:%9:3KENB0
MRM-HU]=7T5IJD:QW$,CR6$LZ(DT#2,OF+O\ PG_X+L_$SQ5\1/#G[-?_  31
M^$-_)!\4/V\OBII&B^+I=+NY8K[P_P# 3P;?6E]XTUIIX9%^QP:S?+:V<<TB
MR076F:=K4*J'0E/E_P#X+?\ P0^"7A[Q1_P1/_9S\3:?8:3^S[H_QNU_X4:_
MI-SK&H^%](A^&6G>&OA1H>H07WB#2M1TG4]$MSIT"O/JMGJEE<6@:6[^U*4;
M=IEV0_7'DL<1BJE"OG4LSKT*-.A&M)9=EV'KS6*C3E."E*OB,/7ITJ;LW[-S
MYII\BK&9G]5>.E"DJJP5/!<R<N6#J8S$0IJ"FHRM*$*D9R=WHU=134C^FC3_
M (N?#/5]2MM)TGXE_#W5=0OYEM]/T_3?&WAJ_P!3O;IP0EM:V-MJ<MQ<S2'Y
M4A@ADD8MA%R<CJ+?Q3H-UKMSX8AUS1IO$ME9QZEJ'AV#5;"77[+2Y]J0ZA>:
M-'</J$%A</)"D%Y<6JPN\\2I)F0 _B=\ /\ @FI_P1*^&WQR^&7Q#_9ZTGX<
M_P#"[/!?BR#7_AN='_:Y^,7CG4!XGTJ*ZN+>2V\'ZO\ &G7]$U\P10W5R]C>
MZ#JD*?9EN##M@(/Y ?M]:5^UU8?\%Q?VB/C+^Q%=_:_CC^S)^R7\*?CK>> I
M3<7,'Q?^&FEQ> _!/Q%^'+Z()8++79;_ $/QHFK1Z'=RPR7@TN2Z\/7-MXUL
M?#,\-X'(<-F&,Q&"H8W%8.&'RRKF-/$YQ@EEJJU:5;#X>&'J).<8TJ]2NH+$
MN+C&44Y-/F<9J9C4PN&J8FO3IU(?6G3MAL3];?LVFVX<D%[T(QE+V*YM(M-W
M5W_:2\TH*JJ+M.,C* $,P'/^Z#O/&TA65N.:Y2/X@^#)=%U/Q#!XS\(RZ'HM
MW]CUK6U\4:,^BZ+=Q3I;SVNJZHM\]G87:32I UK=7$4BS.D3(K,%/R5^P-^W
M)\)/V_/@#H/QM^&-W]@U!0N@_$?X?7[>7XD^&/Q!M;?R]>\):Y:RD7+11W8G
MN-$U/RXX=5TXK,BQSQW5O;?C'_P1D^ 7PG_:B_8T_P""@?P)^.'ARZ\9?"WQ
M[^W5\:;3Q=X;@\4>*_#%SJ-MI?C"SU^P1?$'A+6-!\1:;Y6IZ5I]R5TO581-
M'";6820S31-Q_P!D3IT\RKX^6(P?]CXG 8;%T(TE.LEC*]:$ZOLG.+G.E3I0
MJ4XQFXUJ=:G)2Y)*3Z/K\)5,)1H6J2QE#%UL/.4N55'AU1;@W:3N_;*]DW!1
MDFGK;^C4?&[X.$$CXO?# 'GC_A/_  BQ/( S_P 3< =\D#)X&   -71?B=\/
M_%5^-*\*^._!7B75/L[W3:=X?\5Z#K>H):QR*DMT;+3;^ZG^S1M+&DDQB,:,
MZ*Q&X5_')_P57_X)8?L+?LQ?'/\ X)L>"_@I\&M5\(>&OVA_VHM#^''Q<TRX
M^+WQK\2MXN\&WNN^$=/FT2&\\6?$+79O#;RQZK=8O_#W]GWZ>8TGG.5*-_1S
M^RS_ ,$HOV#_ -B_XH2?%[]F[X*ZM\/OB#+H&J>#I-<O?C'\;_'D+>&M8N[&
MYU"P&B_$+XC>*-$W7,VFVCQW[Z>^I6PB\N"Z2*1XWZLQRO)<%E>!S&CF>;UY
MYA2Q57"4,1E&'P]*3PN,CAI1K5H8^=2-W4YHR5-N+CR.+;NLL'C,=B<5B<-7
MPN&H/".@ISABU7YW6I>T5J<:,''X9)*;5_L[GWOX?\7^'/%:7K^&?$6@>(HM
M/O)]/OY= UO3]8CT^_A16?3[U]-N+E+.]BP/-LYV6>)22T:JP-/U[Q9X?\,V
MEI?>)/$&A^'+6]N8M/M+C7=6L-&M[K4)Y2D%E:W&H3P1W%[<;3Y-E$7FF(^1
M&Q7\P'_!O)\:/@]\,?@_^V?IGQ)^*WP^\!:CJ7[:GQ/O[&P\9>--%\/7MY8K
M(;,7MG;:UJ-O<W%GYUO+#Y\8:(O#)&S@C:>R_P""_P#\<O@W\3?V?/V7](^'
M'Q8^'7CK5[7]M+X*ZC<:5X-\::%K^HP:=#J%VDU[-9Z1J-Q<I:1RSP+-/*BP
MJ\J G/%=4^$\53XBCD//C)4'B516:RP5:$)0^I?6W5=Z3HQB[JFG&I;E4)J7
M,Y.4?VUA99=_:"=-<T(R]A[2G[6,)XE87FY/:3E92;:ERVELM78_I5GUFVM9
M[:TN;RPM[JZ=UM+>:\AADNG5F+16L;,&G9$:)B(@Q!88XQB_Y[!<.V&*#C"%
M%P =W( 4G+<DXXYR #7Y[_M]^"?$&I_!G0/BOX(DFC\<_ #Q%HOQ)T7R7EAD
MNM'T]-.C\3Z9(8WC-Q:7-A&+EX\L7:)<+A&-;?Q^_:8TW0_V/7^-?@Z9;S5_
MB/X3T72/ ,%H/-EE\5>-XAIMI#%")"P?2;F74Y+F,MNB;3W$A5U<KSX/AK$8
M["\/U<OKSQ=?.,UJY!6HJ%Y8+,7.G4PSG-+DE2Q&7RJ9C%R4)I87%TXQ=*C*
M</B\T\1L)D.:\;8+/,*\!A.%.&,'QAA<;%\[SW(IQQ.$S'ZG2TFL=EV>T,+D
M7LTG&KB,QP;5O:6G]QV>JVVH;I+*\MKN.*6:WD:TN8;A$FB )BEDA,BB6,$,
MR,ZN-V2I )"7>KVUBUO%=WEI;37<@AMHKJZAADNG=X8TCM8Y)(S<R%Y8X@L0
M+F614P690?R'_89M/%_[,WQH\3_LL?$K7KK5W^(_@32/C1X*U._:XV3^(/[.
MLX/%^D64[S28E"QW\%S&3A3X6$@(\P>9Z-=W<G[0_P#P4&L+2WNGN/AS^Q[X
M7N+[4X8ED:QUGXK>*A';6%O=,^U9%T1C->HH\S[/=>&H[C!2[2O1Q?!RP>;Y
MMAXYS#%Y)EN15>(,/GF&P\U0Q^"]A3I8)4J550FJF.SFI_9-*#DXPQ,*DKRC
M!G@Y9XN3S'ACAG'5N':V6\6<0<98+@;&<'8G,:*QV1Y[+$8C$9U1Q.*C3J1J
M4<BX:H+B/$5J<'3KX2M2=&I"%6G-_I;?:Q9:9 UYJ6HV>F6D1C$MW>7$-I;(
M9'5(8VN+IDC0S,P1$9@6W93/E@K:FOTMK62[N;J*&WCMY+B6ZE=(X(HHHS(T
M\DC#RHXDC D:1V6-45G)558U^3W[?DOBCXZ>,OAE^Q?\--;DTG7O$T.L?%/Q
MU?QR2Q+IWAWPQI^H3>&K34Y()87^Q7VN>1(L*JS27KZ+MVQK*DWOO[(/Q(A_
M:!_9M_X1SXA6S3^*?#EGKGP8^*NAWI\JZEU/3;*Y\/7BW*I))L&K:-<($D#-
MN=GEVY&#SXKA7$X3AC*N)J^-H26*Q%)X_+:$'+&Y=E>+JXG#99F^(IRG%2PV
M9ULOS2.%@DI?[)3E4Y/K=%/LRSQ3HYGXB\1< X?*,13CE665O[)XAQ.,IO*<
M]XGRRAAL3Q1PS0K0HR^KXSARAF_#=;&U)J:4,SQ/LXR> KQ7V_:WT<]LLL%Q
M#=0RA6AF@F2ZAE0LJ!XY8 (V3<"/E8@,N 2.!#<:S;6MU!8W-[907-[O^RP2
MWD,-S<K&N7^S0RNLLTJJ-Q$,;@'(8'M^=7[ VNZYX+L/BG^ROXSU6[U7Q1\
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M&4),[[)3F$&IJ3878+,QCMI)6<$994B)E#D[1F10RR%N@<D$E0QN@%6!5L#
M# Y.>"N,G +!CDE0 <X) '/TC^QU^SAXH_:__:G^"O[.'A6UDDG^)?C'3+/7
MKR%)@-"\#Z0LFN?$;Q9>[HIX[;2_#_A&SU&]+3RK]HU![73+5)+JY@1_W[$X
MVEAL'7QF*E0HT,'1JU*\U&%*-.C1C&=.,5%*,ISY/906C<G!:>[%_EL:4\4J
M5*G/%XC%XFM#"\E9U,1&,JTZ?+*$DY.%.5DJLW;EY8MP:CS+_3D_8;@U.T_8
MO_9'AUB1Y-4A_9F^!<5]+(<.TR_#+PTN77&Y9-NS>K!2I)5R6!([S]I#X[^"
M?V8O@=\3?C]\18M>E\!_"CPO<^,?%Y\,Z<NKZW:Z%I\UO#J%]8:7]HLVU!]/
M@FDO[BVCN8YI+6UF$&^;RXG]6\/Z-IF@Z+I6@:+!%::+H>EZ;HNDVD*+'%9Z
M9IEE;V=A;QH%156"VMX80FT;%0 !<!:EUS0-&\2Z1J6A>(-+T[6]#UJQN=-U
MK1M7LK?4=*U?3;V![>\L-1L+M);6[LKJ&1X[BVGCDCEC8HRX-?QS5E"KB*U6
M5W2JXBK5:A[K=.I7K5&DW=1ER56DW%VDKM:'](PA4AAH4X-1K4\-"G"4ESQC
M5A2C%.45*,IP52.L4XN4+I23=U_'_P#\%AM+_P"";WB'X(K_ ,%'/V,?VC/A
MC\+_ -M#PSXB\)>)?A5XN^ ?B:TM/$GQ>UK4-7L5ET?Q)X$TF9;@>)[2QNY-
M;N-:U'2+66Y33G\/>*K/5K74(;-?7?\ @OYK^L^.?^"?O_!/3Q)\:M#LO#/B
M;QK\<?V?-:^+GAB^#VEEH6N^*O UAJ'Q$\.W22R0M90:;=7^MV,\DKH;*&V;
M>0R[&_9SP5_P2-_X)Q_#OXFV/Q>\&_LC_"+1O'NEZNNNZ7J:Z)-=V&FZO&PD
MMM0L-!O+N;1;.YM'C$EH\-@/LLH5X0C#(^D_VB?V3/V?/VM/"FC^"/VBOAEX
M?^*OA30==7Q+H^B>)!=M:V.NI9SV"ZA$;2YMI!.MG<S0'<SJ0[':&YKZREQ%
M@<-B,@=)9EB:&38W&8EXC'3P53'/#XC#2I4<OHRIQEST,'4Y:]*>)K3?.I)1
MIQE[OCU,KQ,J>8^S>7TZN/PU&#A##XF&%EB:4HRGB*]*-9.3KI.,W#WU'E3G
M/E;E^1OPR_9+_P"#?;P'\2OA_P"-?A;%^R;IOQ/\,^+]"U;X>W^E?'&\N=6L
M_&:7D46@RZ38S>.[F&XU,WTL<=E:M:2"2XD2%(2S*H^Y?^"H/[)$'[:W[$GQ
MK^#4-O(GC.'0KGQO\*-0C=TU#3/B7X%CDUOPK+:7/E3W,<VHW=K)I+O 49HM
M1,1*JC,>:T7_ ((T?\$Q_#&NZ%XHT/\ 9 ^%NFZ]X8UW1O$NA:E!;ZJMQI^M
MZ#J5MJVDZC&?[4=3-8ZA:6UU%O4H9(1N4C(/Z7"!5PRNQ<2<Y);YMV[<(P54
M,S.6<A3N/S-T"5XV*S::QN78W"YGG&,Q."JTJU*KF]2,W15"M"<:&'E&K6M2
MG!U82@^6T.10CNSOH85NA5HXBA@Z3JKDE]4C-0J1Y(KGG&=.#YH35X7<W[JN
MV]#^3_\ X(7Z5\8OVZOVFOB5_P %*/VF;5IM9^ 'PC^'?[$?P7L9(KI+/3?$
MO@SPG:K\6]>M%NK@RV^M&XU;5M7UB6:+R;G5OB]KUC!##;>'M+EN?4?^#A'1
M_AIXF^-G_!(KPY\:1H8^$?B#]I[Q]H_Q-3Q/J!TCPXW@N_T_X9Q:]#KNII=V
M#:;ILNGM)]IOA>1&UC)<;EQC^BWX9_![X;?!KP]?>&/A?X0T;P1X=U/Q1XM\
M;7VBZ!:"RLKGQ9X[UV[\3^+M<FA1F\R]UK7-0NKZX9B5C,B0PK'#$D:^4_M)
M?L6?LO?M@Z?X.TO]I;X/^%?B[8^ +_6-2\'6OBF*[E70[W7[6SL-:N+4VUW;
MLQU"UL[&&=92ZE;>';MP".^/$U"7%-'-Y86IA\%A</6PN%P>$<6\)A99?C\/
M3AAW4DH)PQ.85L3*3DG*<U9)Q37+4RJ7]CU,O52&)Q#Y)NMC(N4<35IXBC6B
M\2J=FX25&G!V]Y1BEK;E/S0_9T_97_X(3?#/X[?#GQM^SA;_ ++UG\=M%\3G
M_A5MSX6^--WXA\20^)M9LKO1;>WT'1KWQQJD-WJ-_:7E[9V]FEC-YJR2>2I=
MLUYA\&29O^#EK]KZ-7(D'_!-[P:.$=2C#QQ^SR1O<KC)5U("2!@&<D!@&'Z"
M?#S_ ()&?\$X?A+X\\&_$_X=?LH?##PCX_\ A_XBTOQ;X2\4:59ZBE_HGB31
MI_M.DZO;>;J4B-<Z=<!I+5IDD$3MD+@FOJO2/V:O@EH7Q]\2_M1:5X!T:T^/
M?C/P+9?#/Q-\38UN1KVK> M/O-%U&R\,W!-P;3^SX;OP[HTRE+=9=]C%F0[F
M!YZV;T8QS"4,3F^8RQF15LLA5S*M1E5PU:IC,)7BJ+A4K/ZI"&&;4*DW+VE6
M;Y;13FJ6755'"QG2R_"1HX^6)G1R^G6IT:M/ZO6HJ-13Y7*JW54^:"A%.,G>
M[BU^"'[<_P"S9\6/^"8?[1.H_P#!5G]A[PT=<^%.MW$"?M[?LLZ/OT_0O%?A
M&>[ U3XL^%[2R!73K_2VN9=7U"]M+&ZD\'>(<>+Y]/UGP;=^+])M>D_X-N_$
MNE^,_P!F7]JCQGHBW0T;QG^V=\5_%6D)?Q00WL-EXG^QZ[8P7\=N3 +NTBU"
M&&Z,#M#)/$[)+,CF63^BS4=.L-6M;RPU*WMM0LKZTN+'4+&[A2ZLKNPO8O)O
M;2\M9E:"XM+NW,D%Q#*C)+;RRQNI1WSX?\ ?V6O@)^RQX9USP;^S]\,_#OPM
M\+>)?$][XPUG0O#$$\&G7?B/445;K45@GN)EMW:*.*-(;?RH(HHU2*)%50"M
MQ-#%9)7R_&X5RS)SR^C1S-1]^IE^ G6J4\+BK?QJM*=>U'%24Z[P\*>'J5'3
MHTXK59?5IYG0Q=*LHX.E1Q=\'R)N.(Q#H14Z%1Q3I4W"$G.G%I.:;<FI67X8
M_P#!==D;]IG_ ((UR[7"?\-P^$LETDQL_P"$N\ [@Q&=K!29$##]XJG'  /]
M)'608//F<CW1\-S[_P (''&!@"O!/B]^S!\"/CUXA^%OBOXO_#K0O''B#X)^
M+;?QQ\+-4UE;MI_!GBNVGM;J+6M+,%Q"AO8Y[&T<&82Q@PJ/+VD9^@&100V[
M:XZ9&0'+!L$ C.21T//K7F8S,88[+\GP<(5%/+:68TZLI12I3^MXZ&*IN'-)
M3;2B^9324;+78ZJ&'J4L7C:\FN3$2PCIV;;_ '-"=.:DGHKRDM%KJD_A/XS/
M^")O_!-[]BC]M#X??M=^-OVE_@5X>^*?BKPM^V'\4/"V@ZSJ>O>,]*NM+\/F
M\DU1M-0>'_$NEVTL<E]=3WC2/:*Y,@0.5!ST_P#P66_X)I?L1_L:?"+]FOXB
M_LT? 71?A;XVUW]KSX-^#]3UJQ\2^,=5GO?#M_J<M[>:8+?Q/XCUO38EN9[&
M!S<+8F>$1$1NI8,O]2'P"_9:^ ?[+6D^+]$^ ?PWT'X::5X]\7ZAX]\86.@_
M:_)USQCJJ(FH:]>?;+JZ;[;=+&JOL=(CM4[1@YN_'G]FKX(?M.:#X<\,_'7X
M?Z+\1= \(^+-'\=^'=+UO[3Y&E>+M"D:72-=MFL[BWD%Y8M)(82S/'\[91NW
MTL^,,54XCCF;K9F\J52'_"=+'57#V4<MA@I05-8CV2C*I%32M;DY?=NK'ETL
MBPU++5@E3H2KJE&E'$2I0Y[0Q7UFFG-4U-QB^6\>9W<6THZ6]'O='T_Q#X<N
M- U:TCNM,U;0Y-,U.W<@B>QU"P%I<0L#U$D3O&3D< ,,<5^$?P-^$?Q)UO\
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MX2U_Q3XEU-]5U_6;VUN/M&IW[10P&[N1%>1(;@Q6\2N\852R;@@R%'IGPF^
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"_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
